An oral heme oxygenase inhibitor targets immunosuppressive perivascular macrophages in preclinical models of cancer | Science Translational Medicine
A small-molecule heme oxygenase inhibitor disrupts perivascular macrophage–mediated suppression of T cell responses in preclinical models of cancer.
